500 related articles for article (PubMed ID: 12029549)
21. [Analysis of factors affecting treatment results for toxic goiter with radioactive 131I].
Listewnik MH
Ann Acad Med Stetin; 2000; 46():109-21. PubMed ID: 11712298
[TBL] [Abstract][Full Text] [Related]
22. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
Muratet JP; Daver A; Minier JF; Larra F
J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
[TBL] [Abstract][Full Text] [Related]
23. Thyroid imaging using positron emission tomography--a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis.
Flower MA; Irvine AT; Ott RJ; Kabir F; McCready VR; Harmer CL; Sharma HL; Smith AG
Br J Radiol; 1990 May; 63(749):325-30. PubMed ID: 2198979
[TBL] [Abstract][Full Text] [Related]
24. Metastatic follicular carcinoma of the thyroid: reappearance of radioiodine uptake.
Oyen WJ; Mudde AH; van den Broek WJ; Corstens FH
J Nucl Med; 1995 Apr; 36(4):613-5. PubMed ID: 7699452
[TBL] [Abstract][Full Text] [Related]
25. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
26. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J
Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937
[TBL] [Abstract][Full Text] [Related]
27. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
28. Low-activity (124)I-PET/low-dose CT versus (131)I probe measurements in pretherapy assessment of radioiodine uptake in benign thyroid diseases.
Westphal JG; Winkens T; Kühnel C; Freesmeyer M
J Clin Endocrinol Metab; 2014 Jun; 99(6):2138-45. PubMed ID: 24606104
[TBL] [Abstract][Full Text] [Related]
29. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
[TBL] [Abstract][Full Text] [Related]
30. Disseminated bone metastases from occult thyroid cancer effectively treated with debulking surgery and a single dosimetry-guided administration of radioiodine.
Borsò E; Boni G; Mazzarri S; Cocciaro A; Gambacciani C; Traino AC; Manca G; Grosso M; Scatena C; Ortenzi V; Vannozzi R; Marzola MC; Rubello D; Mariani G
Rev Esp Med Nucl Imagen Mol; 2015; 34(2):111-5. PubMed ID: 25455505
[TBL] [Abstract][Full Text] [Related]
31. Stunning effects after a diagnostic dose of iodine-131.
Kao CH; Yen TC
Nuklearmedizin; 1998 Jan; 37(1):30-2. PubMed ID: 9467167
[TBL] [Abstract][Full Text] [Related]
32. [F-18-FDG PET in autonomous goiter].
Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
Nuklearmedizin; 1999; 38(1):1-6. PubMed ID: 9987775
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic scintigraphy and effectiveness of 131I radioiodine therapy in differentiated thyroid carcinoma (DTC)].
Bałdys-Waligórska A; Buziak-Bereza M; Huszno B; Wilczak A
Endokrynol Pol; 2006; 57(4):380-5. PubMed ID: 17006840
[TBL] [Abstract][Full Text] [Related]
34. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
35. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
36. [Non-iodine-absorbing metastasis of differentiated thyroid cancer--therapeutic probe with 13-cis retinoic acid].
Kaniewski M; Czetwertyńska M; Godlewska P; Drac-Kaniewska J
Wiad Lek; 2001; 54 Suppl 1():297-300. PubMed ID: 12182038
[TBL] [Abstract][Full Text] [Related]
37. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
38. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
[TBL] [Abstract][Full Text] [Related]
39. [Results of radioiodine therapy in patients with pulmonary metastases of differentiated thyroid cancer].
Ono Y; Yamamoto Y; Nishiyama Y; Nakano S; Takahashi K; Kawasaki Y; Satoh K; Ohkawa M; Tanabe M
Kaku Igaku; 2000 Nov; 37(6):661-70. PubMed ID: 11193452
[TBL] [Abstract][Full Text] [Related]
40. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
